Cargando…

Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis

In patients with IPF, pirfenidone reduces objective 24-h cough counts and improves subjective measures of cough http://ow.ly/iiGu30f7Pea

Detalles Bibliográficos
Autores principales:	van Manen, Mirjam J.G., Birring, Surinder S., Vancheri, Carlo, Vindigni, Virginia, Renzoni, Elisabetta, Russell, Anne-Marie, Wapenaar, Monique, Cottin, Vincent, Wijsenbeek, Marlies S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2017
Materias:	Agora
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678896/ https://www.ncbi.nlm.nih.gov/pubmed/29051272 http://dx.doi.org/10.1183/13993003.01157-2017

Ejemplares similares

Cough in idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2016)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

The use of online visual analogue scales in idiopathic pulmonary fibrosis
por: Moor, Catharina C., et al.
Publicado: (2022)

Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2019)

Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis
por: Jacob, Joseph, et al.
Publicado: (2019)

Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial
por: Molina-Molina, Maria, et al.
Publicado: (2023)

Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis
por: Stewart, Iain D., et al.
Publicado: (2021)

FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change
por: Nathan, Steven D., et al.
Publicado: (2020)

Single-cell RNA sequencing identifies G-protein coupled receptor 87 as a basal cell marker expressed in distal honeycomb cysts in idiopathic pulmonary fibrosis
por: Heinzelmann, Katharina, et al.
Publicado: (2022)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent
Publicado: (2013)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
por: Lancaster, Lisa H., et al.
Publicado: (2017)

The respiratory microbiota during and following mechanical ventilation for respiratory infections in children
por: de Koff, Emma M., et al.
Publicado: (2021)

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour
por: Sun, Thomas Yang, et al.
Publicado: (2022)

Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
por: Kato, Kosuke, et al.
Publicado: (2021)

Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis
por: Hughes, Dominic A., et al.
Publicado: (2021)

Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19
por: Combet, Margot, et al.
Publicado: (2020)

Bile acid aspiration in people with cystic fibrosis before and after lung transplantation
por: Brodlie, Malcolm, et al.
Publicado: (2015)

Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population
por: Taylor-Robinson, David C., et al.
Publicado: (2014)

An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter
por: Davies, Gwyneth, et al.
Publicado: (2020)

Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?
por: Eapen, Mathew Suji, et al.
Publicado: (2020)

Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021)

Health risks related to polyurethane foam degradation in CPAP devices used for sleep apnoea treatment
por: Palm, Andreas, et al.
Publicado: (2022)

In vivo demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography
por: Si-Mohamed, Salim, et al.
Publicado: (2020)

Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension
por: Sitbon, Olivier, et al.
Publicado: (2020)

Intrapulmonary shunt measured by bedside pulse oximetry predicts worse outcomes in severe COVID-19
por: Kotwica, Aleksandra, et al.
Publicado: (2021)

Chronic breathlessness: re-thinking the symptom
por: Macnaughton, Jane, et al.
Publicado: (2018)

COVID-19: opacification score is higher in the right lung and right lung involvement is a better predictor of ICU admission
por: Nagra, Deepak, et al.
Publicado: (2020)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
por: Aimo, Alberto, et al.
Publicado: (2022)

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
por: Moor, Catharina C., et al.
Publicado: (2017)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
por: Takeda, Yoshito, et al.
Publicado: (2014)

Job strain and COPD exacerbations: an individual-participant meta-analysis
por: Heikkilä, Katriina, et al.
Publicado: (2014)

Does a single Pseudomonas aeruginosa isolation predict COPD mortality?
por: Boutou, Afroditi K., et al.
Publicado: (2014)

Supporting progress towards the post-2015 targets and regional tuberculosis elimination: a statement of intent from the third meeting of the Asian TB Experts Community
por: Mori, Toru, et al.
Publicado: (2015)

Noninterventional statistical comparison of BTS and CHEST guidelines for size and severity in primary pneumothorax
por: Nikolić, Marko Z., et al.
Publicado: (2015)

Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
por: Wells, Charles D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7bvdf14ungr1em9l1tpd4lgaf7